NDAORALTABLET
Approved
May 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ADVIL CONGESTION RELIEF (ibuprofen, phenylephrine hydrochloride) by GSK is cyclooxygenase inhibitors [moa]. Approved for these symptoms associated with the common cold, flu: headache fever sinus pressure nasal congestion minor body aches, pains reduces swelling of the nasal passages temporarily restores freer breathing through the nose. First approved in 2010.
Drug data last refreshed 7h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Advil Congestion Relief is an oral tablet combining ibuprofen (NSAID) and phenylephrine hydrochloride (decongestant) approved in 2010. It treats common cold and flu symptoms including headache, fever, sinus pressure, nasal congestion, and minor body aches by reducing inflammation and temporarily restoring nasal airflow. The ibuprofen component works via cyclooxygenase inhibition to reduce pain and fever.
LOE Approaching
As LOE approaches, the commercial team faces declining revenue opportunities; expect right-sizing and transition focus to pipeline or adjacent products.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Worked on ADVIL CONGESTION RELIEF at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.